More than one-quarter of patients with metastatic prostate cancer present with a synchronous second primary malignancy, according to a review published in The Journal of Urology.

Kyo Chul Koo, M.D., Ph.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues conducted a retrospective record review of 582 consecutive patents with prostate cancer diagnosed with metastasis. 

The authors examined the prognostic impact of a synchronous second primary malignancy, defined as a cytologically or histologically proven solid malignancy, on overall survival.

Continue Reading

The researchers found that 28.1 percent of patients had a synchronous second primary malignancy, of which the most prevalent types were colorectal (9.1 percent), stomach (7.3 percent), and lung (7.1 percent) cancers.

During a median follow-up of 34.1 months, the rate of overall survival was significantly higher for patients without a synchronous secondary primary malignancy versus those with lung or stomach cancer.

RELATED: Under, Over Imaging Suspected for Prostate Cancer Care

Outcomes were comparable for men without a second malignancy and for those with colorectal cancer. Independent predictors of overall mortality included clinical stage T4 or greater, American Society of Anesthesiologists score 1 or greater, and lung or stomach cancer.

“A substantial proportion of patients with metastatic prostate cancer present with a synchronous second primary malignancy,” the authors write.

“Definitive therapy targeting prostate cancer may confer a limited survival benefit in patients with synchronous lung or stomach cancer.”


  1. Koo, Kyo Chul, et al. “Prognostic Impact of Synchronous Second Primary Malignancies on the Overall Survival of Patients with Metastatic Prostate Cancer.” The Journal of Urology. DOI: [epub ahead of print]. October 23, 2014.